| 51 |
25295126 | A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer. | 2014 Sep |
1 |
| 52 |
25361624 | Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. | 2014 Dec |
1 |
| 53 |
25374921 | PI-3 kinase p110β: a therapeutic target in advanced prostate cancers. | 2014 |
1 |
| 54 |
22552048 | Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. | 2013 Nov |
1 |
| 55 |
23319868 | Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. | 2013 |
1 |
| 56 |
23371447 | Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. | 2013 Apr |
1 |
| 57 |
23898269 | Metastatic castration-resistant prostate cancer: two case reports of dramatic response with abiraterone acetate in patients heavily pretreated with chemotherapy. | 2013 May |
1 |
| 58 |
24271422 | Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. | 2013 Dec |
2 |
| 59 |
24314737 | [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results]. | 2013 Oct |
1 |
| 60 |
24314739 | [CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway]. | 2013 Oct |
1 |
| 61 |
24482578 | Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. | 2013 Jul 10 |
1 |
| 62 |
21986558 | Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. | 2012 Sep 5 |
1 |
| 63 |
22064602 | The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. | 2012 Feb |
1 |
| 64 |
22149426 | Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. | 2012 Jan |
1 |
| 65 |
22170708 | Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. | 2012 Feb |
4 |
| 66 |
22198164 | Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. | 2012 Mar |
1 |
| 67 |
22222232 | Human steroid biosynthesis for the oncologist. | 2012 Feb |
1 |
| 68 |
22291466 | Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. | 2012 |
2 |
| 69 |
22327837 | The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. | 2012 May |
1 |
| 70 |
22373838 | Therapeutic options for advanced prostate cancer: 2011 update. | 2012 Apr |
1 |
| 71 |
22430753 | [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer]. | 2012 Feb |
2 |
| 72 |
22451619 | Abiraterone in prostate cancer: a new angle to an old problem. | 2012 Apr 1 |
2 |
| 73 |
22825325 | Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. | 2012 Sep |
1 |
| 74 |
23355790 | Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. | 2012 Dec |
1 |
| 75 |
23795335 | Abiraterone for the Treatment of Advanced Prostate Cancer. | 2012 Sep 1 |
2 |
| 76 |
21243537 | Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. | 2011 Apr |
1 |
| 77 |
21372223 | New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. | 2011 Apr 1 |
1 |
| 78 |
21455038 | Contemporary management of metastatic castration-resistant prostate cancer. | 2011 May |
1 |
| 79 |
21860772 | Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines. | 2011 Jul |
1 |
| 80 |
21985170 | Abiraterone acetate: in metastatic castration-resistant prostate cancer. | 2011 Oct 22 |
1 |
| 81 |
20159814 | Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. | 2010 Mar 20 |
1 |
| 82 |
20159823 | Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. | 2010 Mar 20 |
2 |
| 83 |
20159824 | Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. | 2010 Mar 20 |
2 |
| 84 |
20225998 | Abiraterone acetate for castration resistant prostate cancer. | 2010 Apr |
2 |
| 85 |
20465382 | Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. | 2010 May |
2 |
| 86 |
20524793 | New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. | 2010 Jul |
1 |
| 87 |
20645691 | Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer. | 2010 Jul |
2 |
| 88 |
18957947 | Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? | 2009 Jan |
1 |
| 89 |
19223900 | CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. | 2009 Mar 10 |
1 |
| 90 |
19470933 | Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. | 2009 Aug 10 |
3 |
| 91 |
19509232 | Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. | 2009 Jun 15 |
2 |
| 92 |
19719456 | Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. | 2009 Dec |
1 |
| 93 |
19995520 | Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71. | 2009 Jul |
1 |
| 94 |
19995526 | Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. | 2009 Oct |
1 |
| 95 |
20050017 | Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71. | 2009 Jan |
1 |
| 96 |
18645193 | Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. | 2008 Oct 1 |
4 |
| 97 |
19189435 | Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven. | 2008 Dec |
1 |